|
Aug 28
|
Delcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
|
|
Aug 28
|
Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients
|
|
Aug 27
|
Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients
|
|
Aug 26
|
Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors
|
|
Aug 12
|
Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
May 15
|
Delcath Systems Inc (DCTH) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ...
|
|
May 14
|
Delcath Systems Reports First Quarter 2024 Results and Business Highlights
|
|
May 7
|
Delcath Systems to Host First Quarter 2024 Earnings Call
|
|
May 6
|
Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT
|
|
Apr 4
|
Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Mar 26
|
Delcath Systems Inc (DCTH) Reports Mixed Year-End Financials Amidst Strategic Advancements
|
|
Mar 26
|
Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
|
|
Mar 23
|
Insiders of Delcath Systems Getting Good Value On Their US$736.5k Investment
|
|
Mar 20
|
Delcath Systems Closes $7 Million Private Placement
|
|
Mar 19
|
Delcath Systems to Host Fourth Quarter and Full Year 2023 Results and Business Update Call
|
|
Mar 18
|
Delcath Systems Appoints Martha S. Rook as Chief Operating Officer
|
|
Mar 15
|
Delcath Systems Announces $7 Million Private Placement
|
|
Mar 8
|
Delcath Systems to Participate in Upcoming Investor Conferences
|
|
Jan 16
|
Delcath Systems Announces U.S. Launch and First Commercial Treatment Utilizing HEPZATO KIT™
|
|
Jan 12
|
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|